- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Klinischer Studienfortschritt beflügelt Avalyn Pharma Aktie | 2 | Investing.com Deutsch | ||
| 17.06. | Avalyn Pharma completes enrollment in pulmonary fibrosis trial | 1 | Investing.com | ||
| 17.06. | Avalyn Pharma Inc.: Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis | 540 | GlobeNewswire (Europe) | BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment... ► Artikel lesen | |
| 17.06. | Avalyn Pharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.06. | Avalyn Pharma Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.06. | Avalyn Pharma reports Q1 results | 4 | Seeking Alpha | ||
| 03.06. | Avalyn Pharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Avalyn Pharma Inc.: Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights | 277 | GlobeNewswire (Europe) | On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable... ► Artikel lesen | |
| AVALYN PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.05. | This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 1 | Benzinga.com | ||
| 26.05. | Morgan Stanley startet Coverage für Avalyn Pharma mit "Overweight" und 84 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 26.05. | Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating | 2 | Investing.com | ||
| 25.05. | Jefferies stuft Avalyn Pharma nach Daten zu Lungenkrankheit mit "Buy" ein | 2 | Investing.com Deutsch | ||
| 25.05. | Jefferies initiates Avalyn Pharma stock with buy on lung disease data | 2 | Investing.com | ||
| 25.05. | Guggenheim stuft Avalyn Pharma mit "Kaufen" ein und sieht großes Potenzial bei Fibrose-Medikamenten | 5 | Investing.com Deutsch | ||
| 25.05. | Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs | 1 | Investing.com | ||
| 21.05. | Avalyn Pharma to present 4-year AP01 data at EULAR conference | 2 | Investing.com | ||
| 21.05. | Avalyn Pharma Inc.: Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 | 2 | GlobeNewswire (USA) | ||
| 01.05. | Avalyn Pharma: Erfolgreicher Börsengang an der NASDAQ bringt 345 Millionen US-Dollar ein | 3 | Investing.com Deutsch | ||
| 01.05. | Avalyn Pharma closes $345 million IPO on Nasdaq | 2 | Investing.com | ||
| 01.05. | Avalyn Pharma Inc.: Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,35 | 0,00 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| AMGEN | 316,75 | -0,03 % | Amgen - AMGN: Pharma-Aktie mit Cup & Handle! | Fliegt der Deckel bald weg? Kursziel Allzeithoch! Amgen (AMGN) erhöht Dividenden seit 2011! Dividendenrendite 2025: 2.91 Prozent! Amgen (AMGN) - US0311621009 Rückblick: Bei dem schwachen US-Gesamtmarkt... ► Artikel lesen | |
| NOVAVAX | 8,120 | -1,46 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| BIOGEN | 190,12 | +0,56 % | Biogen Inc.: Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen | Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer's disease, including clinical, biomarker and safety results for Biogen's investigational tau-targeting ASO, following topline... ► Artikel lesen | |
| VIKING THERAPEUTICS | 34,200 | +0,15 % | Abnehm-Medikamente: Milliardenmarkt Adipositas: Der nächste Herausforderer für Novo und Lilly? | © Foto: JoNel Aleccia - picture alliance / ASSOCIATED PRESSViking Therapeutics startet die klinische Prüfung eines neuen Adipositas-Wirkstoffs. Damit wächst die Konkurrenz im Milliardenmarkt für Adipositas-Therapien.Viking... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 14,960 | +0,94 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| TEMPUS AI | 50,38 | -0,51 % | Biovica International: Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI | UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announces that it has, by... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,790 | +0,48 % | BioCryst Pharmaceuticals, Inc.: BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility | -Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth- -Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,60 | 0,00 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| EXELIXIS | 48,105 | +1,00 % | Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty | ||
| SAREPTA THERAPEUTICS | 15,880 | +1,02 % | Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,420 | -3,14 % | Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report | ||
| ATAIBECKLEY | 4,640 | +0,43 % | AtaiBeckley to join Russell 2000, 3000 indexes |
AVALYN PHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 32,940 Euro und damit +0,06 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVALYN PHARMA INC finden Sie auf Wallstreet Online.